The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF).

Trial Profile

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 May 2017

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms DANNOAC-AF
  • Most Recent Events

    • 30 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 28 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top